Should patients with polycystic ovary syndrome be treated with metformin?: Benefits of insulin sensitizing drugs in polycystic ovary syndrome - Beyond ovulation induction

Human Reproduction

Volumn 17, Issue 12, 2002, Pages 3016-3025

  Stadtmauer, Laurel A ^a   Wong, Benjamin C ^a   Oehninger, Sergio ^a  

^a The Jones Institute for Reproductive Medicine   (United States)

Author keywords

Hyperandrogenism; Insulin resistance; Metformin; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; BIGUANIDE; CLOMIFENE CITRATE; FOLLITROPIN; GONADOTROPIN; INSULIN; LACTIC ACID; LEPTIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; ANTIDIABETIC AGENT;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DATA BASE; DOSE CALCULATION; DRUG EFFECT; DRUG USE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GASTROINTESTINAL DISEASE; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LACTIC ACIDOSIS; LONG TERM CARE; MENSTRUAL CYCLE; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY DIABETES MELLITUS; REVIEW; SPONTANEOUS ABORTION; BLOOD; CARDIOVASCULAR DISEASE; FEMALE;

ANDROGENS; CARDIOVASCULAR DISEASES; FEMALE; FERTILIZATION IN VITRO; GONADOTROPINS; HUMANS; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; INSULIN; INSULIN RESISTANCE; LEPTIN; MENSTRUAL CYCLE; METFORMIN; OVULATION INDUCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME;

EID: 0036902675     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Açbay, O. and Gundogdu, S. (1996) Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil. Steril., 65, 946-949.
2. Acien, P., Quereda, F., Matallin, P., Villarroya, E., Lopez-Fernandez, J.A., Acien, M., Mauri, M. and Alfayate, R. (1999) Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: A heterogenous group of disorders. Fertil. Steril., 72, 32-40.
3. Alessi, M.C., Juhan-Vague, I., Kooistra, T., Declerck, P.J. and Collen, D. (1988) Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2. Thromb. Haemost., 60, 491-494.
4. Andersen, P., Seljeflot, I., Abdelnoor, M., Arnesen, H., Dale, P.O., Lovik, A. and Birkeland, K. (1995) Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism, 44, 611-616.
5. Argaud, D., Roth, H., Wiernsperger, N. and Pye, S. (1993) Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur. J. Biochem., 213, 1341-1348.
6. Asunción, M., Calvo, R.M., San Millan, J.L., Sacho, J., Avila, S. and Escovar-Morreale, H.F. (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasion women from Spain. J. Clin. Endocrinol. Metab., 85, 2434-2438.
7. Atiomo, W.U., Fox, R., Condon, J.E., Shaw, S., Friend, J., Prentice, A.G. and Wilkin, T.J. (2000) Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin. Endocrinology, 52, 487-492.
8. Attia, G.R., Rainey, W.E. and Carr, B.R. (2001) Metformin directly inhibits androgen production in human thecal cells. Fertil. Steril., 76, 517-524.
9. Barash, I.A., Cheung, C.C., Weigle, D.S., Ren, H., Kabigting, E.B., Kuijper, J.L., Clifton, D.K. and Steiner, R.A. (1996) Leptin is a metabolic signal in the reproductive system. Endocrinology, 137, 3144-3147.
10. Barbieri, R.L., Makris, A. and Ryan, K.J. (1984) Insulin stimulates androgen accumulation in incubations of human stroma and theca. Obstet. Gynecol., 64 (S3), 73-80.
11. Barbieri, R.L., Smith, S. and Ryan, K.J. (1988) The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil. Steril., 50, 197-212.
12. Brzechffa, P.R., Jakimiuk, A.J., Agarwal, S.K., Weitsman, S.R., Buyalos, R.P. and Magoffin, D.A. (1996) Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 81, 4166-4169.
13. Caro, J.F., Sinha, M.K., Kolaczynski, J.W., Zhang, P.L. and Considine, R.V. (1996) Leptin: The tale of an obesity gene. Diabetes, 45, 1455-1462.
14. Chu, N.V., Caulfied, M., Kong, A.P.S., Mudaliar, S.R., Kim, D.D., Reitz, R., Armstrong, D., Henry, R.R., Baxi, S., Reaven, P.D. and Deutsch, R. (2002) Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care, 25, 542-549.
15. Cibula, D., Cifkova, R., Fanta, M., Poledne, R., Zivny, J.A, nd Skibova, J. (2000) Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum. Reprod., 15, 785-789.
16. Crave, J.C., Fimbel, S., Lejeune, H., Cugnardey, N., Dechaud, H. and Pugeat, M. (1995) Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J. Clin. Endocrinol. Metab., 80, 2057-2062.
17. Dahlgren, E., Janson, P.O., Johansson, S., Lapidus, L. and Oden, A. (1992a) Polycystic ovary syndrome and risk for myocardial infarction: Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet. Gynecol. Scand., 71, 599-604.
18. Dahlgren, E., Johansson, S., Lindstedt, G., Knutsson, F., Oden, A., Janson, P.O., Mattson, L.A., Crona, N. and Lundberg, P.A. (1992b) Women with polycystic ovary syndrome wedge resected in 1956 to 1965: A long-term follow-up focusing on natural history and circulating hormones. Fertil. Steril., 57, 505-513.
19. Dahlgren, E., Janson, P.O., Johansson, S., Lapidus, L., Lindstedt, G. and Tengborn, L. (1994) Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil. Steril., 61, 455-460.
20. De Leo, V., La Marca, A., Ditto, A., Morgante, G. and Cianci, A. (1999) Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil. Steril., 72, 282-285.
21. Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 346, 393-403.
22. Diamnati-Kandarais, E., Kouli, C., Tsianateli, T. and Bergiele, A. (1998) Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur. J. Endocrinology, 138, 269-274.
23. Diamanti-Kandarakis, E., Spina, G., Kouli, C. and Migdalis, I. (2001) Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J. Clin. Endocrinol. Metab. 86, 3595-3598.
24. Dominguez, L.J., Davidoff, A.J., Srinivas, P.R., Stanley, P.R., Walsh, M.F. and Sowers, J.R. (1996) Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rate vascular smooth muscle. Endocrinology, 137, 113-121.
25. Dunaif, A., Graf, M., Mandeli, J., Laumas, V. and Dobrjansky, A. (1987) Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J. Clin. Endocrinol. Metabol., 65, 499-507.
26. Dunaif, A., Segal, K. and Shelly, D. (1992) Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes, 41, 1257-1266.
27. Dunaif, A., Xia, J., Book, C.B., Schenker, E. and Tang, Z. (1995) Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J. Clin. Invest., 96, 801-810.
28. Ehrmann, D.A., Cavaghan, M.K., Imperial, J., Sturis, J., Rosenfield, R.L. and Polonsky, K.S. (1997a) Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 82, 524-530.
29. Ehrmann, D.A., Schneider, D.J., Sobel, B.E., Cavaghan, M.K., Imperial, J., Rosenfield, R.L. and Polonsky, K.S. (1997b) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 82, 2108-2116.
30. El Orabi, H., Ghalia, A.A., Khalifa, A., Mahfouz, H., El Shalkani, A. and Shoieb, N. (1999) Serum leptin as an additional possible pathogenic factor in polycystic ovary syndrome. Clin. Biochem. 32, 71-75.
31. Fleming, R., Hopkinson, Z.E., Wallace, A.M., Greer, I.A. and Sattar, N. (2002) Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab., 87, 569-574.
32. Franks, S. (1989) Polycystic ovary syndrome: A changing perspective. Clin. Endocrinology, 31, 87-120.
33. Franks, S., Gilling-Smith, C., Watson, H. and Willis, D. (1999) Insulin action in the normal and polycystic ovary. Endocrinol. Metab. Clin. North Am., 28, 361-378.
34. Fremark, M. and Bursey, D. (2001) The effects of metformin on body mass index and glucose tolerance in obsess adolescents with fasting hyperinsulinemia and a family history of Type 2 diabetes. Pediatrics, 107, E55.
35. Gharani, N., Waterworth, D.M., Batty, S., White, D., Gilling-Smith, C., Conway, G.S., McCarthy, N., Franks, S. and Williamson, R. (1997) Association of the steroid synthesis gne CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum. Mol. Genet., 6, 397-402.
36. Glueck, C.J., Wang, P., Fontaine, R., Tracy, T. and Sieve-Smith, L. (1999a) Metformin-induced resumption of normal mense in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism, 48, 511-519.
37. Glueck, C.J., Wang, P., Fontaine, R.N., Sieve-Smith, L., Tracy, T. and Moore, S.K. (1999b) Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism, 48, 1589-1595.
38. Glueck, C.J., Awadalla, S.G., Phillips, H., Cameron, D., Wang, P. and Fontaine, R.N. (2000) Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage. Fertil. Steril., 74, 394-397.
39. Glueck, C.J., Phillips, H., Cameron, D., Sieve-Smith, L. and Wang, P. (2001) Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: A pilot study. Fertil. Steril., 75, 46-52.
40. Glueck, C.J., Wang, P., Kobayashi, S., Phillips, H. and Sieve-Smith, L. (2002a) Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil. Steril., 77, 520-525.
41. Glueck, C.J., Sieve-Smith, L., Goldenberg, N. and Wang., P. (2002b) Normal growth in the first year of life in 154 infants with gestation >37 weeks and whose mothers with polycystic ovary syndrome conceived on and took metformin during pregnancy. J. Invest. Med., 50, 172A.
42. Godsland, I.F. and Crook, D. (1994) Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. Am. J. Obstet. Gynecol., 170, 1528-1536.
43. Godsland, I.F., Walton, C., Felton, C., Proudler, A., Patel, A. and Wynn, F. (1992) Insulin resistance, secretion and metabolism in users of oral contraceptives. J. Clin. Endocrinol. Meta., 74, 64-70.
44. Guzick, D.A., Talbott, E.O., Sutton-Tyrrell, K., Herzog, H.C., Kuller, L.H. and Wolfson, S. K. Jr (1996) Carotid atherosclerosis in women with polycystic ovary syndrome: Initial results from a case-control study. Am. J. Obstet. Gynecol., 174, 1224-1229.
45. Haffner, S.M., Valdez, R.A., Hazuda, H.P., Mitchell, B.D., Morales, P.A. and Stern, M.P. (1992) Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes, 41, 715-722.
46. Haffner, S.M. (1996) The insulin resistance syndrome revisited. Diabetes Care, 19, 275-277.
47. Homburg, R. (2002) Should patients with polycystic ovarian syndrome be treated with metformin? A note of cautious optimism. Hum. Reprod., 17, 853-856.
48. Hundal, H.S., Ramlal, T., Reyes, R. and Leiter, L.A. (1992) Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology, 131, 1165-1173.
49. Ibáñez, L., Aulesa, C., Potau, N., Ong, K., Dunger, D.B. and de Zegher, F. (2002) Plasminogen activator inhibitor-1 in girls with precocious pubarche: A premenarcheal marker for polycystic ovary syndrome? Pediatr. Res., 51, 244-248.
50. Ikeda, T., Iwata, K. and Murakami, H. (2000) Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem. Pharmacol., 59, 887-890.
51. Jakubowicz, D.J., Iuorno, M.J., Jakubowicz, S., Roberts, K.A. and Nestler, J.E. (2002) Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 87, 524-529.
52. Kirpichnikov, D., MeFarlane, S.I. and Sowers. J.R. (2002) Metformin: An update. Ann. Intern. Med., 137, 25-33.
53. Klip, a., Gumà, A., Ramlal, T., Bilan, P.J., Lam, L. and Leiter, L.A. (2002) Stimulation of hexose transport by metformin in L6 muscle cells in culture. Endocrinology 130, 2535-2544.
54. Knochenhauer, E.S., Key, T.J., Kahsar-Miller, M., Waggoner, W., Boots, L.R. Azziz, R. (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J. Clin. Endocrinol. Metab., 83, 3078-3082.
55. Koivunen, R.M., Morin-Papunen, L.C., Ruokonen, A., Tapanainen, J.S. and Martikainen, H.K. (2001) Ovarian steroidogenic response to human chorionic gonadotrophin in obsese women with polysystic ovary syndrome: Effect of metformin. Hum. Reprod., 16, 2546-2551.
56. Kolodziejczyk, B., Duleba, A.J., Spaczynski, R.Z. and Pawelczyk, L. (2000) Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil. Steril., 73, 1149-1154.
57. Kupferminc, M.J., Eldor, A., Steinman, N., Many, A., Bar-Am, A., Jaffa, A., Fait, G. and Lessing, J.B. (1999) Increased frequency of genetic thrombophilia in women with complications of pregnancy. N. Engl. J. Med., 240, 9-13.
58. La Marca, A., Egbe, T.O., Morgante, G., Paglia, T., Cianci, A., De Leo, V. and Ciani, A. (2000) Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gondotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum. Reprod., 15, 21-23.
59. Lanzone, A., Fulghesu, A.M., Andreani, C.L., Apa, R., Fortini, A., Caruso, A. and Mancuso, S. (1990) Insulin secretion in polycystic ovarian disease: Effect of ovarian suppression by GnRH agonist. Hum. Reprod., 5, 143-149.
60. Large, V. and Beylot, M. (1999) Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin. Diabetes, 48, 1251-1257.
61. Legro, R.S., Kunselman, A.R., Dodson, W.C. and Dunaif, A. (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucoise tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab., 84, 165-169.
62. Legro, R.S., Kunselman, A.R. and Dunaif, A. (2001) Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med., 111, 607-613.
63. Leroith, D., Werner, H., Beitnenr-Johnson, D. and Roberts, C.T. Jr. (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev., 16:143-163.
64. Livingstone, C. and Collison, M. (2002) Sex steroids and insulin resistance. Clin. Sc., 102, 151-166.
65. Mather, K.J., Verma, S., Corenblum, B. and Anderson, T.J. (2000) Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 85, 1851-1856.
66. Miles, R.A., Gentzschein, E.B.A., Cassidenti, D.L., Stanczyk, F.Z., Carmina, E. and Lobo, R.A. Cutaneous application of an androstenedione gel as an in vivo test of 5α-reductase activity in women. (1992) Fertil. Steril., 58, 708-712.
67. Miyazaki, H., Matsuoka, H., Cooke, J.P., Usui, M., Ueda, S., Okuda, S. and Imaizumi, T. (2000) Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation, 99, 1141-1146.
68. Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E. and Muggeo, M. (2000) Metformin effects on clinical features, endocrine and metabolic profiles and insulin sensitivity in polycystric ovary syndrome: A radomized, double bl ind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab., 85, 139-146.
69. Morin-Papunen, L.C., Koivunen, R.M., Ruokonen, A. and Martikainen, H.K. (1998a) Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Feretil. Steril., 69, 691-696.
70. Morin-Papunen, L.C., Koivunen, R.M., Tomas, C., Ruokonen, A. and Martikainen, H.K. (1998b) Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 83, 2566-2568.
71. Morin-Papunen, L.C., Vauhkonen, I., Koivunen, R.M., Ruokonen, A., Martikainen, H.K. and Tapanainen, J.S. (2000) Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 85, 3161-3168.
72. Nestler, J.E. (2002) Should patients with polycystic ovarian syndrome be treated with metformin? Hum. Reprod., 17, 1950-1953.
73. Nestler, J.E. and Jakubowicz D. (1997a) Decrease is ovarian cytochrome P450c17a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N. Engl. J. Med. 335, 617-623.
74. Nestler, J.E. and Jakubowicz, D.J. (1997b) Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P459c17alpha activity and serum androgens. J. Clin. Endocrinol. Metab. 82, 4075-4079.
75. Nestler, J.E., Jakubowicz, D.J., Evans, W.S. and Pasquali, R. (1998) Effects of metformin on spontaneous and clomiphine-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med., 338, 1876-1880.
76. Nestler, J. E., Stovall, D., Akhter, N., Iurno, M.J. and Jakubowicz, D.J. (2002) Should patients wtih polycystic ovarian syndrome be treated with metformin? An enthusiastic endorsement. Hum. Reprod., 17, 1950-1953.
77. Nordt, T.K., Sawa, H., Fujii, S. and Sobel, B.E. (1995) Induction of plasminogen activator inhibitory type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation, 91, 764-770.
78. Paradisi, G., Steinberg, H.O., Hempfling, A., Cronin, J., Hook, G., Shepard, M.K. and Baron, A.D. (2001) Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103, 1410-1415.
79. Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V. Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G.E., Filicorio, M. and Morselli-Labate, A.M. (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 85, 2767-2774.
80. Petruzelli, L.M., Stadtmauer, L., Herrera, R. and Rosen, O.M. (1985) The insulin receptor is a tyrosine-specific protein kinase. In Smith Kline and French Symposiun: Mechanisms of Receptor Regulation. pp. 53-64.
81. Piacquadio, K., Hollingsworth, D.R. and Murphy, H. (1991) Effects of inutero exposure to oral hypoglcaemic drugs. Lancet, 338, 866-869.
82. Pirwany, I.R., Yates, R.W., Cameron, I.T. and Fleming, R. (1999) Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. Hum. Reprod., 14, 2963-2968.
83. Polderman, K.H., Gooren, L.J., Asscheman, H., Bakker, A. and Heine, R.J. (1994) Induction of insulin resistance by androgens and estrogens. J. Clin. Endocrinol. Metab., 79, 265-271.
84. Radziuk, J. (2000) Insulin sensitivity and its measurement: Structural commonalities among the methods. J. Clin. Endocrinol. Metab., 85, 4426-4433.
85. Radziuk, J., Zhang, Z., Wiernsperger, N. and Pye, S. (1997) Effects of metformin on lactate uptake and gluconeogenesis in the perfused rate liver. Diabetes, 46, 1406-1413.
86. Sampson, M., Kong, C., Patel, A., Unwin, R. and Jacobs, H.S. (1996) Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin. Endocrinology, 45, 623-629.
87. Sattar, N., Hopkinson, Z.E. and Greer, I.A. (1998) Insulin-sensitising agents in polycystic ovary syndrome. Lancet, 351, 305-307.
88. Schardein, J.L. (1993) Chemically Induced Birth Defects. 2nd edn, Mercel Dekker, New York, USA.
89. Schneider, D. and Sobel, B. (1991) Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type-1: Implications for vascular disease in hyperinsulinemic states. Proc. Natl Acad. Sci. USA, 88, 9959-9963.
90. Serafini, P., Ablan, F. and Lobo, R.A. (1985) 5&-reductase activity in the genital skin of hirsute women. J. Clin. Endocrinol. Metab., 60, 349-355.
91. Sheppard, T.H. (1995) Catalog of Teratogenic Agents. 8th edn. Johns Hopkins University Press, Baltimore, MD, USA.
92. Slowinska-Srzednicka, J., Zgliczynski, S., Wierzbicki, M., Srzednicki, M., Stopinska-Gluszak, U., Zgliczynski, W., Soszynski, P., Chotkowska, E., Bednarska, M. and Sadowski, Z. (1991) The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. J. Endocrinol. Invest., 14, 569-575.
93. Stadtmauer, L.A. and Rosen, O.M. (1986) Increasing the camp content of IM 9 cells alters the phosphorylation state and protein kinase activity of the insulin receptor. J. Bio. Chem., 256, 9266-9273.
94. Stadmauer, L.A., Toma, S.K., Riehl, R.M. and Talbert, L.M. (2001) Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin like growth factors. Fertil. Steril., 75, 505-509.
95. Stadtmauer, L.A., Toma, S.K., Riehl, R.M. and Talbert, L.M. (2002) The impact of metformin on ovarian stimulation and outcome in coasted patients with polycystic ovary syndrome undergoing in-vitro fertilization. RBM Online, 5, 112-116.
96. Stith, B.J., Goalstone, M.I., Espinoza, R., Mossel, C., Roberts, D. and Wiernsperger, N. (1996) The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol, 1,4,5,-trisphosphate mass in Xenopus oocytes. Endocrinology, 137, 2990-2999.
97. Stuhlinger, M.C., Abbasi, F., Chu, J.W., Lamendola, C., McLaughlin, T.L., Cooke, J.P., Reaven, G.M. and Tsao, P.S. (2002) Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA, 287, 1420-1426.
98. Talbott, E., Guzick, D., Clerici, A., Berga, S., Detre, K., Weimer, K. and Kuller, L. (1995) Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler. Thromb. Vasc. Biol., 15, 821-826.
99. Talbott, E.O., Zborowski, J.V., Sutton-Tyrell, K., McHugh-Pemu, K.P. and Guzick, D.S. (2001) Cardiovascular risk in women with polycystic ovary syndrome. Obstet. Gynecol. Clin. N. Am., 28, 111-133.
100. Unluhizarci, K., Kelestimur, F. and Bayram, F. (1999) Insulin-sensitizing agents and the polycystic ovary syndrome. N. Engl. J. Med., 335, 657-658.
101. Utiger, R.D. (1996) Insulin and the polycystic ovary syndrome. N. Engl. J. Med., 335, 657-658.
102. Velazquez, E.M., Mendoza, S., Hamer, T., Sosa, F. and Glueck, C.J. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism, 43, 647-654.
103. Velazquez, E., Acosta, A. and Mendoza, S.G. (1997a) Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet. Gynecol., 90, 392-395.
104. Velazquez, E.M., Mendoza, S.G., Wang, P. and Glueck, C.J. (1997b) Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism, 46, 454-457.
105. Waterworth, D.M., Bennett, S.T., Gharani, N., McCarthy, M.I., Hague, S., Batty, S., Conway, G.S., White, D., Todd, J.A., Franks, S. and Williamson, R. (1997) Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet, 349, 986-990.
106. Wilcock, C. and Bailey, C.J. (1991) Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J. Pharm. Pharmacol., 43, 120-121.
107. Wild, R.A., Painter, P.C., Coulson, P.B., Carruth, K.B. and Ranney, G.B. (1985) Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 61, 946-951.
108. Wiernsperger, N.F. and Bailey, C.J. (1999) The antihyperglycaemic effect of metformin: Therapeutic and cellular mechanisms. Drugs, 58 (S1), 31-39.
109. Wollen, N. and Bailey, C.J. (1988) Metformin potentiates the antigluconeogenic action of insulin. Diabetes Metab., 14, 88-91.
110. Yarali, H., Yildirir, A., Aybar, F., Kabakci, G., Bulukmez, O., Akgul, E. and Ota, A. (2001) Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil. Steril. 76, 511-516.
111. Yarali, H., Yildiz, B.O., Demirol, A., Zeyneloglu, H.B., Yigit, N., Bukulmez, O. and Koray, Z. (2002) Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: A prospective randomized trial. Hum. Reprod., 17, 289-294.
112. Yli-Järvinen, H., Nikkilä, K. and Mälimattila, S. (1999) Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. Drugs, 58 (S1), 53-54.
113. Zhang, L.H., Rodriguez, H., Ohno, S. and Miller, W. (1995) Serine phosphorylation of the human P450c17 increases, 17,20-lyase activity: Implication for adrenarche and the polycystic ovary syndrome. Proc. Natl Acad. Sci. USA, 92, 10619-10623.